A 39-year-old polytransfused patient with aplastic anemia acquired transfusion-associated HTLV-I infection shortly before transplantation. The patient underwent allogeneic bone marrow transplantation and developed HTLV-I associated myelopathy 3 years later. Clinical abnormalities and a host of atypical findings are presented in the context of previous reports describing uncommon features of the disease.
Human T cell leukemia/lymphoma virus type I (HTLV-I) is the first identified retrovirus, isolated from a patient diagnosed with cutaneous lymphoma. 1 HTLV-I is the cause of adult T cell leukemia. In addition, a neurological syndrome characterized by weakness, spasticity and bladder dysfunction due to progressive myelopathy was found to occur in HTLV-I seropositive patients and to be identical with an endemic myelopathy previously known as tropical spastic paraperesis (TSP) . 2 This syndrome has been termed HTLV-I-associated myelopathy (HAM).
HTLV-I infection can be transmitted by transfer of infected lymphocytes occurring during sexual contact, breast feeding and blood product transfusion. HTLV-I infection is endemic in certain geographic areas such as Japan and other parts of the Orient, the Caribbean basin, and central Africa. The incidence of HTLV-I in the USA is low but appears to be increasing, especially among populations with risk factors of multiple parenteral exposure. 3 The prevalence among volunteer blood donors is 0.018%. 3 We report a case of a patient who developed HAM following allogeneic bone marrow transplantation (BMT). To our knowledge, this is the first reported example of such a complication occurring after BMT. 
Case report
In 1986, a 39-year-old Caucasian female, with no significant prior medical history, presented with severe aplastic anemia. She was initially treated with antithymocyte globulin and subsequently with growth factors unsuccessfully. During this time she required multiple blood product transfusions totalling 62 packed red blood cell units and 23 units of platelets. In 1988 she underwent a 6/6 HLA-matched unrelated allogeneic BMT. She achieved adequate engraftment. However, her course was complicated with grade III acute graft-versus-host disease (GVHD) for which she required treatment with cyclosporin A and high doses of corticosteroids. Subsequently, she developed chronic GVHD manifesting as sicca syndrome, scleroderma-like changes, and hepatic dysfunction documented by liver biopsy.
Approximately 3 years after BMT, she developed slowly progressing symmetric weakness which primarily involved her lower extremities and was more pronounced in proximal muscles. No sensory deficits or cranial nerve weakness was found. Although she had brisk deep tendon reflexes (3+ throughout) and a jaw jerk sign, she had normal tone and no Babinski sign. Diffuse muscle wasting, with increase of muscle tone was noted. At that time, she was taking 40 mg of prednisone every other day for treatment of chronic GVHD. It was assumed that her weakness was at least partially due to steroid-induced myopathy. Although her steroid dose was reduced, 6 months later she became wheelchair bound with inability to flex her hips against gravity. Further work-up included normal thyroid function tests; normal CPK and aldolase; no elevation of antinuclear antibodies titer, mild IgG kappa monoclonal gammopathy without elevation of total IgG, normal serologic screen for anti-myelin antibodies. Nerve conduction studies showed low amplitude in the motor nerves of the lower extremities but not in the upper extremities. Electromyogram showed evidence of chronic neuropathic changes in all extremities characterized by polyphasic potentials, poor recruitment and increased motor unit potential amplitudes. An MRI of the spine revealed the presence of compression fractures of the superior endplates of T12 and L4 vertebrae, without cord compression. A MRI of the brain showed scattered white matter lucencies, resembling multiple ischemic insults. A biopsy of the left gastrocnemius muscle showed an unusual pattern of type I/type II fiber atrophy with microvascular and arteriolar hyalin thickening. There was no evidence of inflammation. Electron microscopy demonstrated that this thickening was not due to amyloid deposition. The exact nature of the hyalin deposition remains unclear.
During this work-up, information was obtained that one of the RBC transfusion units given 4 months prior to BMT had been HTLV-I positive. HTLV-I serology was obtained and was found to be positive. Examination of cerebrospinal fluid (CSF) showed WBC: 13/l, 97% mononuclear cells, 3% lymphocytes, no atypical forms, normal protein and glucose concentrations. CSF was negative for VDRL as well as oligoclonal bands, but tested positive for HTLV-I antibodies. HTLV-I sequences were amplified from CSF samples using PCR amplification technique for HTLV-I/II tax sequences. Furthermore, restriction digestion techniques were used which disclosed the presence of HTLV-I.
Upon completion of the above work-up, it was believed that the patient had developed HTLV-I associated myelopathy. Corticosteroids were reinstituted at a dose of 80 mg of oral prednisone daily, with no improvement. Prednisone was subsequently tapered and a course of danazole was initiated, with special attention to her liver function. She tolerated a stepwise increase to a dose of 200 mg three times a day for a period of 2 years with a brief interruption due to jaundice. The patient initially reported some symptomatic improvement, and with the aid of a physical therapist, was able to make some steps. However, during this time she developed a neurogenic bladder. Her neurologic condition has stabilized.
Discussion
We describe a patient who developed transfusion-associated HTLV-I associated myelopathy (HAM) after bone marrow transplantation for aplastic anemia. The patient acquired the infection prior to blood screening for HTLV-I. Even after the implementation of routine HTLV-I screening in November 1988, the current risk for HTLV-I infection in the USA is estimated to be 1 in 70 000 transfusions. Development of HAM following transfusion-associated infection has been previously reported to be a rare event. 4 The majority of infections lead to a healthy carrier state. To our knowledge, no patient developing HAM after BMT has been reported, although a seroconversion has been documented. 5 In addition, a case after heart transplant has also been reported. 6 This case presents atypical involvement of the upper extremities and gammopathy. One out of 25 patients with endemic TSP (HAM) from Martinique, also had peripheral nerve involvement with atrophy. 7 Also, motor neurone loss has been demonstrated neuropathologically in the spinal cord of a HAM patient. 8 Two other patients in the cohort from Martinique also developed monoclonal gammopathy, which may have contributed to the peripheral neuropathy. The presence of perivascular thickening with non-amyloid amorphus deposition is of unclear significance. Interestingly, hyalinoid thickening of the small vessels of the spinal cord and the meninges suggestive of angiopathy was noted at the autopsy of one patient with HAM. 8 The relative paucity of sensory symptoms and the sparing of facial nerves is a consistent finding in HAM. With the advent of MRI, white matter lesions commonly seen as small foci of abnormally increased signal, especially in the periventricular space have been documented in a small number of patients or asymptomatic carriers. 9, 10 It is possible that the foci of signal attenuation found in the white matter of the brain of our patient may represent a different stage of HTLV-I associated leukoencephalopathy.
This observation should alert clinicians to the possibility of a dramatic progression of HTLV-I infection in patients who have undergone BMT.
